Payment overview · 2025
General Payments
$749.27
28 reported records · 14 companies
Healthcare provider profile · identity verified
Benjamin Yeboah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW HAVEN, CT · NPI 1174705636
Verified facts
What the public records show
CMS Open Payments records show Benjamin Yeboah, MD received $749.27 in general payments during 2025 across 28 reported records.
Novo Nordisk Inc accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $234.86 | 31.4% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $109.45 | 14.6% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.60 | 11.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $69.45 | 9.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.45 | 5.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.09 | 3.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $25.61 | 3.4% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $25.46 | 3.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.85 | 3.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.39 | 3.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.08 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.87 | 2.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.45 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.66 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $749.27 | 28 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $234.86 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $129.90 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.60 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.45 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $25.46 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.16 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 172 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
109 | 32 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
172 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
129 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 988 | 167 |
| Trazodone Hcl | Trazodone Hcl | 986 | 158 |
| Amlodipine Besylate | Amlodipine Besylate | 928 | 159 |
| Eliquis | Apixaban | 904 | 98 |
| Gabapentin | Gabapentin | 674 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 632 | 101 |
| Furosemide | Furosemide | 594 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 582 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 439 | 71 |
| Mirtazapine | Mirtazapine | 404 | 66 |
| Sertraline Hcl | Sertraline Hcl | 401 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 381 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 378 | 72 |
| Quetiapine Fumarate | Quetiapine Fumarate | 338 | 47 |
| Carvedilol | Carvedilol | 330 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 309 | 56 |
| Lisinopril | Lisinopril | 287 | 55 |
| Metformin Hcl | Metformin Hcl | 287 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 286 | 52 |
| Losartan Potassium | Losartan Potassium | 275 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 260 | 49 |
| Divalproex Sodium | Divalproex Sodium | 225 | 32 |
| Levetiracetam | Levetiracetam | 217 | 26 |
| Potassium Chloride | Potassium Chloride | 209 | 37 |
| Olanzapine | Olanzapine | 207 | 25 |
| Omeprazole | Omeprazole | 205 | 45 |
| Tradjenta | Linagliptin | 202 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 193 | 42 |
| Famotidine | Famotidine | 187 | 36 |
| Farxiga | Dapagliflozin Propanediol | 186 | 23 |
| Risperidone | Risperidone | 186 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 183 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 172 | 32 |
| Donepezil Hcl | Donepezil Hcl | 158 | 24 |
| Allopurinol | Allopurinol | 157 | 30 |
| Finasteride | Finasteride | 154 | 32 |
| Lactulose | Lactulose | 137 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 133 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 132 | 15 |
| Entresto | Sacubitril/Valsartan | 129 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 127 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 22 |
| Montelukast Sodium | Montelukast Sodium | 123 | 24 |
| Memantine Hcl | Memantine Hcl | 122 | 24 |
| Spironolactone | Spironolactone | 122 | 26 |
| Latanoprost | Latanoprost | 117 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 31 |
| Lamotrigine | Lamotrigine | 111 | 12 |
| Prednisone | Prednisone | 110 | 48 |
| Linzess | Linaclotide | 109 | 32 |
| Aripiprazole | Aripiprazole | 108 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 52 |
| Lithium Carbonate | Lithium Carbonate | 103 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 101 | 16 |
| Ozempic | Semaglutide | 95 | 20 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 94 | 49 |
| Baclofen | Baclofen | 90 | 19 |
| Myrbetriq | Mirabegron | 89 | 11 |
| Labetalol Hcl | Labetalol Hcl | 87 | 15 |
| Meloxicam | Meloxicam | 81 | 24 |
| Alprazolam | Alprazolam | 79 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 75 | 15 |
| Anastrozole | Anastrozole | 75 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 28 |
| Trulicity | Dulaglutide | 74 | 17 |
| Topiramate | Topiramate | 73 | 12 |
| Midodrine Hcl | Midodrine Hcl | 71 | 19 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 69 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 11 |
| Nystatin | Nystatin | 68 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 14 |
| Haloperidol | Haloperidol | 64 | suppressed |
| Bupropion Xl | Bupropion Hcl | 63 | 11 |
| Torsemide | Torsemide | 62 | 18 |
| Xarelto | Rivaroxaban | 62 | 16 |
| Clozapine | Clozapine | 60 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 59 | 18 |
| Metformin Hcl Er | Metformin Hcl | 58 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 13 |
| Oxcarbazepine | Oxcarbazepine | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 38 |
| Ezetimibe | Ezetimibe | 53 | 12 |
| Jardiance | Empagliflozin | 53 | 13 |
| Tramadol Hcl | Tramadol Hcl | 53 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 52 | suppressed |
| Lidocaine | Lidocaine | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 50 | 21 |
| Warfarin Sodium | Warfarin Sodium | 50 | suppressed |
| Creon | Lipase/Protease/Amylase | 49 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 48 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 32 |
| Scopolamine | Scopolamine | 48 | 11 |
| Carbamazepine | Carbamazepine | 47 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Ondansetron Odt | Ondansetron | 46 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 44 | 18 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 43 | suppressed |
| Budesonide | Budesonide | 42 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 42 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | 19 |
| Lokelma | Sodium Zirconium Cyclosilicate | 39 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 38 | 15 |
| Lansoprazole | Lansoprazole | 38 | 13 |
| Levocarnitine | Levocarnitine (With Sugar) | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 37 | 12 |
| Rybelsus | Semaglutide | 37 | 11 |
| Paliperidone Er | Paliperidone | 36 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 34 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Tivicay | Dolutegravir Sodium | 33 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 33 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 32 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 17 |
| Simvastatin | Simvastatin | 32 | 12 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 16 |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 13 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Pregabalin | Pregabalin | 28 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Pentoxifylline | Pentoxifylline | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 23 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Primidone | Primidone | 23 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 22 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | 14 |
| Naltrexone Hcl | Naltrexone Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 13 |
| Fluphenazine Hcl | Fluphenazine Hcl | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 15 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Erythromycin | Erythromycin Base | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Procrit | Epoetin Alfa | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 14 |
| Clonazepam | Clonazepam | 18 | suppressed |
| Dexamethasone | Dexamethasone | 18 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 18 | suppressed |
| Risperidone Er | Risperidone Microspheres | 18 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 18 | suppressed |
| Amantadine | Amantadine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 17 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 16 | 12 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 16 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 16 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Perphenazine | Perphenazine | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Acetic Acid | Acetic Acid | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Motegrity | Prucalopride Succinate | 13 | suppressed |
| Nyamyc | Nystatin | 13 | 11 |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Edurant | Rilpivirine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $749.27 · 28 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Hillrom - Carnation Ambulatory Monitor, INGREZZA, INSPIRE, Korlym, LEQVIO, REXULTI, TRELEGY ELLIPTA, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error